Skip to main content
OpenTrials
Completed

NCT Number: NCT00511979

Comparison of the Effect on the Glucose Infusion Rates Between Inhaled Technosphere Insulin and a Subcutaneous Injection of Regular Human Insulin

A prospective, single center, open randomized, six way crossover study comparing the dose response effect of four different doses of Technosphere Insulin after pulmonary function delivery in comparison to s.c. injection of two different doses of regular human insulin.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects must be in good health, as judge by brief history and physical examination.
  • Sex: both, male and female.
  • Age: 18-40 years.
  • Body mass index: 18-27 kg/m2.
  • Capability to reach peak inspiratory flow of >41/sec measured by a computer assisted spirometry.
  • FEV1 equal to or greater than 80% of predicted normal.

Exclusion criteria

  • Diabetes Mellitus type 1 or type 2.
  • Human insulin antibodies.
  • Anamnestic history of hypersensitivity to the study medication or to drugs with similar chemical structures.
  • Having a history of severe or multiple allergies.
  • Treatment with any other investigational drug in the last three months before study entry.
  • Progressive fatal disease.
  • History of significant cardiovascular, respiratory, gastrointestinal, hepatic, renal, neurological, psychiatric and /or hematological disease.
  • Having ongoing respiratory tract infection.
  • Smoker defined as subjects with evidence or history of tobacco or nicotine use in the last year prior to entry in the study.
  • Blood donation within the last 30 days.
  • A woman who is lactating.
  • Pregnant women or women intending to become pregnant during the study.
  • A sexually active woman of childbearing age not actively practicing birth control or using medically accepted device or therapy.
  • A lack of compliance or other reasons, which prevent to the opinion of the investigator the participation of the subject in the study.

Treatment and study plan

Technosphere Insulin

Drug

regular human insulin

Drug

Primary outcomes

  1. Dose-corrected area-under-the serum insulin concentration vs. time curve for inhaled TI and subcutaneous RHI at timepoints -120, -90, -60, 0, 1, 3, 7, 12, 20, 30, 45, 60 and 90 minutes, and 2, 3, 4, 5 and 6 hours relative to treatment

    Time frame: crossover every 3-28 days for up to 20 weeks

  2. Area under the glucose infusion rate for inhaled TI and subcutaneous RHI at timepoints -120, -90, -60, 0, 1, 3, 7, 12, 20, 30, 45, 60 and 90 minutes, and 2, 3, 4, 5 and 6 hours relative to treatment

    Time frame: crossover every 3-28 days for up to 20 weeks

Secondary outcomes

  1. Safety variables included adverse events (AEs), clinical laboratory tests, HbA1c, pulmonary function tests, vital signs, physical examinations, and diabetes-specific signs (ie, hypoglycemia)

    Time frame: crossover every 3-28 days for up to 20 weeks

Sponsors and collaborators

Lead sponsor

Mannkind Corporation

Industry

Registry information

Official study title

Effect of Different Doses of Inhaled Technosphere Insulin on Glucose Infusion Rates During Euglycemic Clamps in Comparison to a Subcutaneous Injection of Regular Human Insulin

Important dates

Study start
1999
Primary completion
2000
Study completion
2000
First posted
Aug 6, 2007
Registry last updated
Jun 26, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.